2020 Annual Meeting | C189 - Assessment of Rapidly Progressive Dementias 1: Prion and Non-prion Neurodegenerative Diseases
| 01:00 PM - 01:05 PM | Introduction |
Introduction to Assessment of Rapidly Progressive Dementia
Michael D. Geschwind, MD, PhD, FAAN |
| 01:05 PM - 01:55 PM | Speaker |
Prion Diseases as Prototypical Rapidly Progressive Dementia
Michael D. Geschwind, MD, PhD, FAAN |
| 01:55 PM - 02:45 PM | Speaker |
Non-prion Neurodegenerative Diseases Causing Rapidly Progressive Dementia
Bradley F. Boeve, MD, FAAN |
| 02:45 PM - 03:00 PM | Q&A |
Questions and Answers
|
| Michael D. Geschwind, MD, PhD, FAAN | Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc.. |
| Bradley F. Boeve, MD, FAAN | Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care. |